Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
Alexios Matikas(Karolinska University Hospital), Theodoros Foukakis(Karolinska Institutet), Thomas Hatschek(Karolinska University Hospital), Ingrid Hedenfalk(Lund University), Zakaria Einbeigi(Sahlgrenska University Hospital), Eleni Lagoudaki(University Hospital of Heraklion), Tobias Lekberg(Karolinska University Hospital), Ariel Saracco(Stockholm South General Hospital), Edward Azavedo(Karolinska Institutet), Lena Carlsson(University of Gothenburg), Mattias Bergqvist(Biovica (Sweden)), Mats Hellström(Karolinska University Hospital), Jonas Bergh(Karolinska Institutet), Judith Bjöhle(Karolinska University Hospital), Ioannis Zerdes(Karolinska University Hospital), Kang Wang(Hebei North University), Niklas Loman(Lund University), S Rotstein(Danderyds sjukhus), Johan Hartman(Karolinska University Hospital), Anna von Wachenfeldt(Karolinska Institutet), Balázs Ács(Karolinska University Hospital)
Cited by 12
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
|New England Journal of Medicine|2007|4.6k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k